175 related articles for article (PubMed ID: 20483992)
1. Vaccination with peptide mimetics of the gp41 prehairpin fusion intermediate yields neutralizing antisera against HIV-1 isolates.
Bianchi E; Joyce JG; Miller MD; Finnefrock AC; Liang X; Finotto M; Ingallinella P; McKenna P; Citron M; Ottinger E; Hepler RW; Hrin R; Nahas D; Wu C; Montefiori D; Shiver JW; Pessi A; Kim PS
Proc Natl Acad Sci U S A; 2010 Jun; 107(23):10655-60. PubMed ID: 20483992
[TBL] [Abstract][Full Text] [Related]
2. A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1.
Lai RP; Hock M; Radzimanowski J; Tonks P; Hulsik DL; Effantin G; Seilly DJ; Dreja H; Kliche A; Wagner R; Barnett SW; Tumba N; Morris L; LaBranche CC; Montefiori DC; Seaman MS; Heeney JL; Weissenhorn W
J Biol Chem; 2014 Oct; 289(43):29912-26. PubMed ID: 25160627
[TBL] [Abstract][Full Text] [Related]
3. A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.
Rubio AA; Filsinger Interrante MV; Bell BN; Brown CL; Bruun TUJ; LaBranche CC; Montefiori DC; Kim PS
J Virol; 2021 Jul; 95(15):e0235020. PubMed ID: 33980592
[TBL] [Abstract][Full Text] [Related]
4. The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat.
Montefiori DC; Filsinger Interrante MV; Bell BN; Rubio AA; Joyce JG; Shiver JW; LaBranche CC; Kim PS
Proc Natl Acad Sci U S A; 2021 Jan; 118(3):. PubMed ID: 33431684
[TBL] [Abstract][Full Text] [Related]
5. A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice.
Qi Z; Pan C; Lu H; Shui Y; Li L; Li X; Xu X; Liu S; Jiang S
Biochem Biophys Res Commun; 2010 Jul; 398(3):506-12. PubMed ID: 20599765
[TBL] [Abstract][Full Text] [Related]
6. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
Nelson JD; Kinkead H; Brunel FM; Leaman D; Jensen R; Louis JM; Maruyama T; Bewley CA; Bowdish K; Clore GM; Dawson PE; Frederickson S; Mage RG; Richman DD; Burton DR; Zwick MB
Virology; 2008 Jul; 377(1):170-83. PubMed ID: 18499210
[TBL] [Abstract][Full Text] [Related]
7. Quaternary protein mimetics of gp41 elicit neutralizing antibodies against HIV fusion-active intermediate state.
Sadler K; Zhang Y; Xu J; Yu Q; Tam JP
Biopolymers; 2008; 90(3):320-9. PubMed ID: 18338371
[TBL] [Abstract][Full Text] [Related]
8. Multiple antigen peptide mimetics containing gp41 membrane-proximal external region elicit broad neutralizing antibodies against human immunodeficiency virus type 1 in guinea pigs.
Zhang L; Miao L; Gong X; Zhang H; Yang L; Shi Y; Kong W; Jiang C; Shan Y
J Pept Sci; 2013 Aug; 19(8):491-8. PubMed ID: 23794478
[TBL] [Abstract][Full Text] [Related]
9. Binding of HIV-1 gp41-directed neutralizing and non-neutralizing fragment antibody binding domain (Fab) and single chain variable fragment (ScFv) antibodies to the ectodomain of gp41 in the pre-hairpin and six-helix bundle conformations.
Louis JM; Aniana A; Lohith K; Sayer JM; Roche J; Bewley CA; Clore GM
PLoS One; 2014; 9(8):e104683. PubMed ID: 25105806
[TBL] [Abstract][Full Text] [Related]
10. Stabilized trimeric peptide immunogens of the complete HIV-1 gp41 N-heptad repeat and their use as HIV-1 vaccine candidates.
Wu C; Raheem IT; Nahas DD; Citron M; Kim PS; Montefiori DC; Ottinger EA; Hepler RW; Hrin R; Patel SB; Soisson SM; Joyce JG
Proc Natl Acad Sci U S A; 2024 May; 121(22):e2317230121. PubMed ID: 38768344
[TBL] [Abstract][Full Text] [Related]
11. Stapled HIV-1 peptides recapitulate antigenic structures and engage broadly neutralizing antibodies.
Bird GH; Irimia A; Ofek G; Kwong PD; Wilson IA; Walensky LD
Nat Struct Mol Biol; 2014 Dec; 21(12):1058-67. PubMed ID: 25420104
[TBL] [Abstract][Full Text] [Related]
12. Sequestering of the prehairpin intermediate of gp41 by peptide N36Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41.
Gustchina E; Bewley CA; Clore GM
J Virol; 2008 Oct; 82(20):10032-41. PubMed ID: 18667502
[TBL] [Abstract][Full Text] [Related]
13. N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies.
Li D; Liu J; Zhang L; Xu T; Chen J; Wang L; Zhao Q
Virol Sin; 2015 Dec; 30(6):449-56. PubMed ID: 26715302
[TBL] [Abstract][Full Text] [Related]
14. Structure-guided stabilization improves the ability of the HIV-1 gp41 hydrophobic pocket to elicit neutralizing antibodies.
Bruun TUJ; Tang S; Erwin G; Deis L; Fernandez D; Kim PS
J Biol Chem; 2023 Apr; 299(4):103062. PubMed ID: 36841484
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a novel multi-immunogen vaccine strategy for targeting 4E10/10E8 neutralizing epitopes on HIV-1 gp41 membrane proximal external region.
Banerjee S; Shi H; Banasik M; Moon H; Lees W; Qin Y; Harley A; Shepherd A; Cho MW
Virology; 2017 May; 505():113-126. PubMed ID: 28237764
[TBL] [Abstract][Full Text] [Related]
16. Reverse Immunology Approach to Define a New HIV-gp41-Neutralizing Epitope.
Dorgham K; Pietrancosta N; Affoune A; Lucar O; Bouceba T; Chardonnet S; Pionneau C; Piesse C; Sterlin D; Guardado-Calvo P; Karoyan P; Debré P; Gorochov G; Vieillard V
J Immunol Res; 2019; 2019():9804584. PubMed ID: 31019982
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 neutralizing antibodies elicited by the candidate CBD1 epitope vaccine react with the conserved caveolin-1 binding motif of viral glycoprotein gp41.
Rey-Cuillé MA; Svab J; Benferhat R; Krust B; Briand JP; Muller S; Hovanessian AG
J Pharm Pharmacol; 2006 Jun; 58(6):759-67. PubMed ID: 16734977
[TBL] [Abstract][Full Text] [Related]
18. Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity.
Bradley T; Trama A; Tumba N; Gray E; Lu X; Madani N; Jahanbakhsh F; Eaton A; Xia SM; Parks R; Lloyd KE; Sutherland LL; Scearce RM; Bowman CM; Barnett S; Abdool-Karim SS; Boyd SD; Melillo B; Smith AB; Sodroski J; Kepler TB; Alam SM; Gao F; Bonsignori M; Liao HX; Moody MA; Montefiori D; Santra S; Morris L; Haynes BF
EBioMedicine; 2016 Oct; 12():196-207. PubMed ID: 27612593
[TBL] [Abstract][Full Text] [Related]
19. Progress towards the development of a HIV-1 gp41-directed vaccine.
McGaughey GB; Barbato G; Bianchi E; Freidinger RM; Garsky VM; Hurni WM; Joyce JG; Liang X; Miller MD; Pessi A; Shiver JW; Bogusky MJ
Curr HIV Res; 2004 Apr; 2(2):193-204. PubMed ID: 15078183
[TBL] [Abstract][Full Text] [Related]
20. Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41.
Gustchina E; Li M; Louis JM; Anderson DE; Lloyd J; Frisch C; Bewley CA; Gustchina A; Wlodawer A; Clore GM
PLoS Pathog; 2010 Nov; 6(11):e1001182. PubMed ID: 21085615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
